CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Glucagon +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03965130
NCT03965130Phase 1Completed

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation and Pyruvate Carboxylase Flux in Man Assessed by Positional Isotopomer NMR Tracer Analysis (PINTA)

Yale University·interventional·Posted May 28, 2019·Updated Nov 26, 2024

In Brief

A Phase 1 clinical trial evaluating Glucagon and Control Study for Healthy Participants. Completed, enrolled 10 participants across 1 site.

Detailed Summary

It is well established that alterations in the portal vein insulin:glucagon ratio play a major role in the dysregulated hepatic glucose metabolism in type 2 diabetes but the molecular mechanism by which glucagon promotes alterations in hepatic glucose production and mitochondrial oxidation remain poorly understood. This is borne out of the fact that both glucagon agonists and antagonists are being developed to treat type 2 diabetes with unclear mechanisms of action. This study will directly assess rates of mitochondrial oxidation and pyruvate carboxylase flux for the first time in humans using PINTA analysis as well as the effects of glucagon. The results will have important implications for the possibility of intervening in the pathogenesis of non alcoholic fatty liver and type 2 diabetes via chronic dual GLP-1/glucagon receptor antagonism and provide an important rationale for why a dual agonist may be more efficacious for treatment of non alcoholic fatty liver and T2D than GLP-1 alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 28, 2019
Enrollment StartJun 5, 2019
Primary CompletionJul 7, 2022
Study CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.1 years ago

Interventions

Glucagonbiological

PINTA study with glucagon

Control Studyother

The same participants will not receive glucagon during the PINTA study